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Background: Human UDP-glucuronosyltransferases (UGTs) are important membrane proteins located in endoplasmic 
reticulum, and play important roles in metabolism of  a variety of  endogenous and exogenous compounds. 
Aims: To determine the influence of  subtle difference in the structure of  oleanolic acid and betulinic acid towards the inhi-
bition towards the activity of  UGT isoforms. 
Methods: In vitro glucuronidation of  4-methylumbelliferone (4-MU) reaction was employed as the probe reaction to deter-
mine the inhibition of  these two compounds towards UGTs’ activity. 
Results: The inhibition of  capability of  oleanolic acid towards UGT1A6 and UGT1A8 were higher than betulinic acid. 
However, no significant difference was observed for the inhibition of  oleanolic acid and betulinic acid towards UGT1A7. 
Furthermore, concentration-dependent behaviour was determined for the inhibition of  oleanolic acid and betulinic acid 
towards UGT1A6 and UGT1A8. At various concentrations of  oleanolic acid and betulinic acid, the inhibition of  oleanolic 
acid towards UGT1A6 and UGT1A8 was higher than betulinic acid. 
Conslusion: Given that UGT1A6 and UGT1A8 play key role in the the inhibition of  oleanolic acid towards UGT1A6 and 
UGT1A8 will induce drug-drug interaction and the risk of  diseases.
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Introduction
Human immunodeficiency virus infection and acquired 
immune deficiency syndrome (HIV/AIDS) is defined 
as a disease spectrum of  the human immune system 
caused by infection with human immunodeficiency vi-
rus (HIV)1,2. Searching the efficient drugs to treat HIV/
AIDS patients is very important and necessary. 
Betulinic acid is a naturally occurring pentacyclic trit-
erpenoid, and has been demonstrated to exhibit an-
tiretroviral, antimalarial, and anti-inflammatory bio-
chemical properties. Betulinic acid has been frequently 
reported to exert anti-tumor activities towards multiple 
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tumor types, including melanoma and breast cancer3,4. 
Oleanolic acid is a naturally occurring triterpenoid iso-
lated from many food and medicinal plants, including 
Olea europaea (leaves, fruit), Rosa woodsii (leaves), 
Prosopis glandulosa (leaves and twigs), Phordendron ju-
niperinum (whole plant), Syzygium claviflorum (leaves), 
Hyptis capitata (whole plant), Mirabilis jalapa and Tern-
stromia gymnanthera (aerial part)5. Oleanolic acid has 
very similar structure with betulinic acid (Figure 1). 
Betulinic acid and oleanolic acid are also the potential 
drug candidates for the treatment of  HIV/AIDS pa-
tients6. 
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The present study aims to investigate the inhibition 
capability of  these two compounds towards the activ-
ity of  drug-metabolizing enzymes UDP-glucuronosyl-





ycoumarin, and uridine-diphospho-glucuronic acid 
trisodium salt (UDPGA) were purchased from Sig-
ma-Aldrich. Recombinant UDP-glucuronosyltrans-
ferase (UGT) isoforms were obtained from BD Gentest 
Corp. (Woburn, MA). All other reagents were of  HPLC 
grade or of  the highest grade commercially available.
Investigation of  the inhibition of  UGTs’ activity by 
oleanolic acid and betulinic acid
For UGT supersomes-catalyzed in 4-MU glucuronida-





tion probe reactions, the incubation system (200 uL) 
is consisted of  0.05 mg/ml UGT supersomes, 5 mM 
UDPGA co-factor, 5 mM of  MgCl2, 50 mM Tris-HCl 
(pH=7.4), and 4-MU in the absence or presence of  
different concentration of  oleanolic acid and betulinic 
acid. The concentration of  used protein and the incu-
bation time can ensure the linear reaction. The concen-
tration of  4-MU was equal to the Km or S50 values 
for each UGT isoform. The analytical conditions have 
been described in the previous literatures7,8. 
Statistical method
The statistical difference was performed using two-
tailed student t-test.
Results
The inhibition screening of  oleanolic acid and betulinic 
acid towards three important UGT isoforms UGT1A6, 
UGT1A7, and UGT1A8 was firstly investigated, and 
the results were given in Figure 2. 
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Figure 2 Initial screening the inhibition capability of oleanolic acid and betulinic acid towards the 
activity of UGT1A6, UGT1A7, and UGT1A8. 100 uM of oleanolic acid and betulinic acid were 









The inhibition of  capability of  oleanolic acid towards 
UGT1A6 and UGT1A8 were higher than betulinic 
acid. However, no significant difference was observed 
for the inhibition of  oleanolic acid and betulinic acid 
towards UGT1A8. Furthermore, concentration-de-
pendent behaviour was determined for the inhibition 
of  oleanolic acid and betulinic acid towards UGT1A6 
and UGT1A8 (Figure 3). 
At various concentrations of  oleanolic acid and betu-
linic acid, the inhibition of  oleanolic acid towards UG-
T1A6 and UGT1A8 was higher than betulinic acid.
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Discussion
Human UDP-glucuronosyltransferases (UGTs) are 
important membrane proteins located in endoplasmic 
reticulum, and play important roles in metabolism of  
a variety of  endogenous and exogenous compounds9. 
Many UGTs-inhibition based adverse effects cases have 
been reported. For example, indinavir, an HIV thera-
peutic drug, can significantly induce the elevation of  
unconjugated bilirubin in serum through inhibition of  
UGT1A1-mediated bilirubin glucuronidation10. 
Many compounds have been reported to exert inhibi-
tion potential towards UGT isoforms, such as warfa-
rin11 and arbidol12. The present study showed that sub-
tle difference for the structure of  oleanolic acid and 
betulinic acid will result in the significant difference of  
these two compounds’ inhibition towards UGT1A6 
and UGT1A8. Besides the high contribution of  these 
two UGT isoforms towards the metabolism of  xenobi-
otics, high correlation between the activity of  these two 
UGT isoforms and cancers was reported. For example, 
UGT1A6_19_GG genotype has been reported to be a 
breast cancer risk factor13. The lower activity of  UG-
T1A8 will increase the risk of  esophageal cancer risk14. 
Therefore, the inhibition of  oleanolic acid towards UG-
T1A6 and UGT1A8 will induce drug-drug interaction 
and the risk of  diseases.
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Figure 3 Concentration-dependent inhibition of betulinic acid and oleanolic acid towards towards 
the activity of UGT1A6 and UGT1A8. 
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